Medicine guide
Lartruvo
·
- Prescription status not stated
- Cancer treatments and immune-system medicines
- Active substance
- Olaratumab
- Made by
- Eli Lilly Nederland B.V.
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Lartruvo is indicated in combination with doxorubicin for the treatment of adult patients with advanced soft tissue sarcoma who are not amenable to curative treatment with surgery or radiotherapy and who have not been previously treated with doxorubicin (see section 5.1).
From the official label · 2026-09-30 · European Medicines Agency
Details
| Made by | Eli Lilly Nederland B.V. |
|---|---|
| Active substance | Olaratumab |
| Used in | Cancer treatments and immune-system medicines |
| Classification | L01XC27 · Cancer treatments and immune-system medicines |
| Additional monitoring ▼ | Yes — under additional monitoring (black triangle). Report suspected side effects. |
| Authorised on | 2016-11-09 |
| Last updated by the regulator | 2019-09-02 |
| EMA product number | EMEA/H/C/004216 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).